GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells $226,837.74 in Stock

Key Points

• Katherine Stueland, the CEO of GeneDx Holdings Corp., sold 2,154 shares of the company's stock for $226,837.74, resulting in a 38.51% reduction in her ownership.
• GeneDx reported a significant earnings beat with $0.50 earnings per share for the quarter, exceeding analysts' expectations of $0.10 and generating revenue of $102.69 million.
• The stock has experienced fluctuations, hitting a recent low of $25.32 and a high of $117.75 over the past year, with analysts giving it a consensus rating of "Moderate Buy."

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 2,154 shares of GeneDx stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $105.31, for a total value of $226,837.74. Following the transaction, the chief executive officer directly owned 3,440 shares in the company, valued at approximately $362,266.40. The trade was a 38.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, July 9th, Katherine Stueland sold 3,220 shares of GeneDx stock. The stock was sold at an average price of $93.00, for a total value of $299,460.00.
• On Tuesday, July 1st, Katherine Stueland sold 9,657 shares of GeneDx stock. The stock was sold at an average price of $90.94, for a total value of $878,207.58.

GeneDx Stock Performance

Shares of NASDAQ:WGS traded down $1.56 during trading on Thursday, hitting $101.95. 1,175,567 shares of the company were exchanged, compared to its average volume of 1,095,327. The company has a market cap of $2.91 billion, a PE ratio of 2,039.00 and a beta of 2.01. The stock has a 50 day moving average of $78.73 and a 200 day moving average of $82.64. GeneDx Holdings Corp. has a 52-week low of $25.32 and a 52-week high of $117.75. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.25 and a quick ratio of 3.07.

GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. The business had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a return on equity of 17.24% and a net margin of 0.39%. As a group, equities research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Jefferies Financial Group raised GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective on the stock in a report on Friday, May 9th. Wall Street Zen cut GeneDx from a "buy" rating to a "hold" rating in a research note on Sunday, July 13th. Wells Fargo & Company upped their price objective on GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday. TD Securities decreased their target price on GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Finally, Guggenheim reiterated a "buy" rating and set a $115.00 target price (up previously from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $94.22.

Institutional Investors Weigh In On GeneDx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sei Investments Co. bought a new position in GeneDx during the 4th quarter valued at about $1,384,000. KLP Kapitalforvaltning AS purchased a new position in shares of GeneDx in the fourth quarter worth $200,000. LPL Financial LLC purchased a new position in shares of GeneDx in the fourth quarter worth $2,738,000. Vanguard Group Inc. raised its holdings in shares of GeneDx by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company's stock worth $77,337,000 after buying an additional 156,768 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of GeneDx by 106.8% in the fourth quarter. JPMorgan Chase & Co. now owns 107,891 shares of the company's stock worth $8,293,000 after buying an additional 55,730 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.